DOCSLIB.ORG

List of International Nonproprietary, United States Adopted, and Trade Names of Some Anthelmintics

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

List of International Nonproprietary, United States Adopted, and Trade Names of Some Anthelmintics International United States Trade names nonproprietary name adopted name Acetarsol Cestarsol, Nemoral, Nemural, Tenoban Albendazole Albendazole Valbacen, Valbazen, Zentel Amidantel Bephenium hydroxynaphthoate - Alcopar, Alcopara, Frantin Bithionol Bithionolate sodium Actamer, Bitin, Lorothidol Bitoscanate Jonit Bromoxanide Bromoxanide Brotianide Bunamidine Bunamidine Ruban, Scolaban hydrochloride Cambendazole Cambendazole Bonlam, Camben, Camdan, Equiben, Nemi­ nil, Porcam 5% Ciclobendazole Ciclobendazole Clioxanide Clioxanide Tremerad Closantel Closantel Flukiver, Seponver Coumafos Asuntol, Baymix, Co-Ral, Meldane, Muscavox Dichlorophen Antiphen, Dicestal, Didroxone, Diphenthane- 70, Parabis, Teniathane, Teniatol, Ver­ miplex Dichlororphenol + bithionol Trematol Dichlorvos Atgard, Dichlorman, Equigard, Equigel, Task, Tenac Diethylcarbamazine Caricide, Dirocide, Hetrazan Difetarsone Bemarsal Dithiazanine iodide Abminthic, Delvex, Deselmine, Dizan, Pankil­ ler, Telmid Erythromycine ( = carbomycin) Erythromycin estolate Magnamycin Febantel Febantel Rintal Febantel + trichlorfon Rintal-plus Fenbendazole Fenbendazole Axilur, Panacur 656 List of International Nonproprietary and Trade Names of Some Anthelmintics (continued) International United States Trade names nonproprietary name adopted name Fenc1ofos Ronnel Dermaphos, Ectoral, Etrolene, Ronnel, Trc lene Flubendazole Flubendazole Flubenol, Flumoxal, Flutelmium, Fluverma Fospirate Fospirate Torelle Haloxon Cavoxon, Equivurm, Eustidil, Galloxon 77' Halox, Helmiren, Loxon, Verloxon Hexachlorophene Bilevon, Distocid, Distodin, Distophen, Fasciobitin, Fasciophene Ivermectin Ivermectin Ivomec, Eqvalan Levamisole Levamisole Anthe1por, Anthesol, Ascaridil, Ascaryl, hydrochloride Aviverm, Aviversol, Citarin-L, Concurat­ Decaris, Decaris vet, Ergamisol, Getevern L, Istamicide, Ketrax, Levipor, Levoriper col, L-Narpenol, L-Ripercol, L-SpartakOl L-Tramisol, Nemaphenine, Nemicanisol, Nemicide, Nemisol, Nilverm, Nilzan, Pa­ gliderm, Paglisol, Pig wormer, Riporon, Solaskil, Stimamizol, Tramisol, Tramizan Vermisol, Wormex Mebendazole Mebendazole Antiox, Equiverm-plus, Fugacar, Gammax, Lomper, Mebatreat, Mebenav, Mebenvet, Muitispec, Nemasole, Noverme, Ovite1mil Pantelmin, Parmeben, Telmin, Te1min-KI­ Telmin RTL, Te1mintic, Vermox, Vermox vet, Verpanil Mebendazole + metrifonate Trichlorfon-Telmin Metyridine Deke1min, Mintic, Promintic Metrifonate (trichlorfon) Bilarcil, Combot, Dipterex, Ditrifon, Dylox, Dyrex, Foschlor, Neguvon, Tugon Morantel Morantel tartrate Banminth II, Bovhelm, Expar, Glylox, Ibantic, Nemante1, Ovithelm, Paratect Naftalofos Amdax, Maretin, Rametin Nic1ofolan Bilevon, Dertil, Distolon Nic10samide Nic10samide Cestocid, Devermin, Lintex, Mansonil, Phe­ nasal, Radeverm, Sagimid, Tredemine, Vermitin, Yomesan Nitrodan Nitrodan Everfree Nitroscanate Nitroscanate Lopatol Nitroxynil Dovenix, Trodax Oxante1 Oxante1 pamoate Oxantel + pyrantel Polbantrin, Quantrel Oxfendazole Oxfendazole Synanthic, Systamex List of International Nonproprietary and Trade Names of Some Anthelmintics 657 continued) lnternational United States Trade names lonproprietary name adopted name )xibendazole Oxibendazole AM 313, Bovinol, Equiminthe, Loditac, Neplon 100 )xibendazole + dichlorvos Equiminthe-plus Dxibendazole + niclosamide Polyverkan Dxyclozanide Diplin, Metiljin, Zanil Oxytetracyline Terramycin Parbendazole Parbendazole Helmatax, Verminum, Wormguard Paromomycin Gabbromycin, Gabbroral, Humagel, Huma- tin Phenothiazine Contaverm, Coopazine, Helmitina, Pheno­ bent, Phenovis Piperazine Adipate: Antivermin, Ascatrix, Coopane, Entacyl, Mapiprin, Pipadox, Piperfesa, Pipradin Citrate: Antelmin, Bryrel, Moncasan, Piperasol, Pi- prelix, Safersol Phosphate: Candizine, Piperazate Sebacate: Nematorazine Praziquantel Praziquantel Biltricide, Cesol, Droncit Promethazine Phenergan Pyrantel Pyrantel pamoate Antiminth, Combantrin, Strongig P Pyrantel tartrate Banminth, Exhelm, Pyrequan, Strongid Pyrantel + oxantel Canex plus Pyrvinium Pamoate: Vanquin, Povan Rafoxanide Rafoxanide Flukanide, Ranide Resorantel Terenol Spiramycin Spiramycin Rovamycin Stilbazium iodide Stilbazium iodide Monopar Tetramisole Tetramisole- Anthelvet, Aviverm, Aviversol, Deltram, hydrochloride Imena, Nemicide, Nilverm, Nilzan, Pig wormer, Ripercol, Strongophenine, Vade­ phen, Vermium Tetramisole + niclosamide Aritene, Stromiten Thenium closylate + Ancaris, Canopar piperazine Tiabendazole Thiabendazole Bovizole, Coglazol, Equizole, Mintizol, Om­ nizole, Thibenzole 658 List of International Nonproprietary and Trade Names of Some Anthelmintics (continued) International United States Trade names nonproprietary name adopted name Tiabendazole + piperazine Equizole A Ticarbodine Ticarbodine Tioxidazole Tioxidazole Uredofos Uredofos Sansalid Vincofos Vincofos SUbject Index Acanthogobius microtubules 127 Heterophyes heterophyes 45 mode of action 127 Acetylcholine 131, 132 mode of administration 204, 258, 354 pyrantel 165 Moniezia 593 Acetylcholinesterase 146 Necator americanus 202-204 pyrantel 165 Nematodirus 414-417,427 Adleriella minutissima Nematospiroides dub ius 127 hosts 527 Oesophagostomum 414-417,427,478 locality 527 Ostertagia 414-417 Alaria alata 528 Ostertagia ostertagi 418 hosts 527 Oxyuris 455 locality 527 Oxyuris equi L4 445 Alariasis 528 Oxyuris equi L5 445 Albendazole 4,454,535,591,598 Paragonimus kellicotti 202 abomasal fluid 126 paramphistomes 523 Ancylostoma canium 202 Parascaris 455 Ancylostoma duodenale 202-204 Parascaris equorum L4 445 Ascaris 478 Parascaris equorum L5 445 Ascaris lumbricoides 257,258 pharmacokinetics 125, 126 Ascaris suum 202 plasma levels 125 assessment 202,257,353 precautions 204,258,284,319,354 Bunostomum 414-417 Probstmayra vivipara 445 cambendazole-resistant H. contortus product names 419 strain 426 resistance 413,426,427 Chabertia 15, 417, 427 ruminal fluid 126 contraindications 204,258,284,319, sheep 126, 127 354 side effects 204,258,284,319,354,641 Cooperia 414-417,427 skeletal abnormalities 127 cost 641 small strongyles L4 445 dosage 204, 258, 354, 446 small strongyles L5 445 Draschia megastoma 445 strongyloides 414-417,426,455 efficacy 593,641 Strongyloides stercoralis 318, 319 embryotoxic effect 408 Strongyloides westeri 445 formulations 419,446 Strongylus edentatus 445 Gaigeria 415,417,427 Strongylus equinus 445 Habronema spp. 445 Strongylus vulgaris 445 Haemonchus 414-417 suppliers 419, 446 hookworms 202, 203 Syphacia obvelata 202 Hymenolepis nana 202 Taenia pisiformis 202 length of treatment 641 Taenia saginata 593 male reproduction 427 Thysanosoma actinioides 593 mass treatment 258, 640, 641 toxicity 593 membrane resistance 127 toxicology 127 Mesocestoides 593 Toxocara 499 660 Subject Index Albendazole dosage 206 Toxocara canis 202 feces 128 trade name 446, 655 filariae 127 Trichostrongylus 414--417,427 hookworms 205 Trichostrongylus axei 445 mode of action 128 Trichuris 478 mode of administration 206 Trichuris trichiura 204, 353 mutagenic activity 128 Trichuris vulpis 202 Necator americanus 205 urine 126 pharmacokinetics 127 Albendazole sulfone 126 precautions 207 Albendazole sulfoxide 126 Schistosoma mansoni 206 Alkaline phosphatases 147 schistosomes 127 Alkaloids 491 side effects 206 Amidantel 128 toxicology 128 Ancylostoma caninum 204 urine 128 Ascaris lumbricoides 204, 258 dosage 205 ' Amphibians mode of administration 205 intermediate host 559 Necator americanus 204 Amphostomiasis side effects 205 clioxanide 533 Strongyloides stercoralis 204 Anacardium occidentale 196 teratogenic effects 129 Ancylostoma toxicology 129 piperazine 491 Toxocara canis 204 Ancylostoma braziliense 191,487-489 Uncinaria stenocephala 204 disophenol 139 Amidostomum 506, 508 tiabendazole 496 Amidostomum anseris Ancylostoma caninum 488, 489, 495 cambendazole 513 albendazole 499 disophenol 512 amidantel 204 fenbendazole 514 bephenium hydroxynaphthoate 207 levamisole 516 congenital infections 29 mebendazole 513 disophenol 139 pyrantel 515 dogs 29.30 trichlorphon 512 immunization 30 Amidostonum anseris ivermectin 500 geese 505 metyridine 493 Amines 470 nitrodan 493 y-aminobutyric acid nitroscanate 587 Angiostrongylus cantonensis 130 praziquantel 164 Ascaris suum 130 pyrantel pamoate 225 Caenorhabditis elegans 131 thenium 493 ivermectin 131 tiabendazole 496 picrotoxin 131 Ancylostoma canium Amminosidin sulphate 595 albendazole 202 Amoebiasis Ancylostoma duodenale 26, 186, 202, 224 prevalence 632 adult worms 191 Amoebotaenia sphenoides albendazole 203, 204 birds 575, 598 amidantel 204 bunamidine hydroxynaphthoate 587 amoscanate 205 di-n-butyl tin dilaurate 598 anemia 30, 31, 191, 193 fowl 598 bephenium hydroxynaphthoate 208, niclosamide 598 631 turkey 598 bephenium hydroxynaphthoate and Amoscanate tetrachloroethylene 232 Ancylostoma duodenale 205 bitoscanate 209,210 assessment 205 blood loss 31 contraindications 207 cachexia montana 31 Subject Index 661 clinical manifestations 30 picrotoxin 131 colostrum 85, 635 praziquantel 164 control 31 tiabendazole 299 coproculture 193 Angiostrongylus costaricencis 296 development 191 adults 297 egg-output 191, 193 clinical symptoms 11, 12 eggs 28,191 definitive hosts 11 epidemiology 28, 29 diagnosis 297 flubendazole 214 eggs 11,297 geographical distribution 27, 193 epidemiology 12 host 191 geographical distribution 11,298 hypobiosis 191 host 297 immunization 30 infection rate 12 infective larvae 635 intermediate host 11 intensity of infections 30 L1 larvae 297 iron 30,31 life cycle
Recommended publications
  • Full Text in Pdf Format

    Full Text in Pdf Format

    DISEASES OF AQUATIC ORGANISMS Published July 30 Dis Aquat Org Oral pharmacological treatments for parasitic diseases of rainbow trout Oncorhynchus mykiss. 11: Gyrodactylus sp. J. L. Tojo*, M. T. Santamarina Department of Microbiology and Parasitology, Laboratory of Parasitology, Faculty of Pharmacy, Universidad de Santiago de Compostela, E-15706 Santiago de Compostela, Spain ABSTRACT: A total of 24 drugs were evaluated as regards their efficacy for oral treatment of gyro- dactylosis in rainbow trout Oncorhj~nchusmykiss. In preliminary trials, all drugs were supplied to infected fish at 40 g per kg of feed for 10 d. Twenty-two of the drugs tested (aminosidine, amprolium, benznidazole, b~thionol,chloroquine, diethylcarbamazine, flubendazole, levamisole, mebendazole, n~etronidazole,mclosamide, nitroxynil, oxibendazole, parbendazole, piperazine, praziquantel, roni- dazole, secnidazole, tetramisole, thiophanate, toltrazuril and trichlorfon) were ineffective Triclabenda- zole and nitroscanate completely eliminated the infection. Triclabendazole was effective only at the screening dosage (40 g per kg of feed for 10 d), while nitroscanate was effective at dosages as low as 0.6 g per kg of feed for 1 d. KEY WORDS: Gyrodactylosis . Rainbow trout Treatment. Drugs INTRODUCTION to the hooks of the opisthohaptor or to ulceration as a result of feeding by the parasite. The latter is the most The monogenean genus Gyrodactylus is widespread, serious. though some individual species have a restricted distri- Transmission takes place largely as a result of direct bution. Gyrodactyloses affect numerous freshwater contact between live fishes, though other pathways species including salmonids, cyprinids and ornamen- (contact between a live fish and a dead fish, or with tal fishes, as well as marine fishes including gadids, free-living parasites present in the substrate, or with pleuronectids and gobiids.
  • Witola, Basis of Anthelmintic Resistance and Development Of

    Witola, Basis of Anthelmintic Resistance and Development Of

    9/8/2016 Basis of Anthelmintic Resistance and Novel Approaches to Development of New Efficacious Anthelmintic Drugs William H. Witola, BVetMed, MSc., Ph.D. Department of Pathobiology College of Veterinary Medicine University of Illinois at Urbana-Champaign E-mail: [email protected] Current Anthelmintics 3 Classes of anthelmintic drugs registered in the USA : 1.) Benzimidazoles • Fenbendazole, Safeguard, Panacur 2.) Macrocyclic Lactones • Avermectins: Ivermectin, Ivomec, Primectin, Privermectin • Eprinomectin: Eprinex • Doramectin: Dectomax • Milbimycins: Moxidectin, Cydectin, Quest 3.) Nicotinic Agonists • Imidothiazoles: Levamisole, Prohibit • Tetrahydropyrimidines: Morantel, Rumatel, Positive Goat Pellet, Goat dewormer, Pyrantel, Strongid Spiroindoles (Not registered in US) Amino-acetonitriles (Not registered in US ) How do anthelmintic drugs kill parasites? • Benzimidazoles (Valbazen, Safeguard): Bind to a parasite protein called β-tubulin leading to collapse of parasite skeleton structure. • Avermectin/Milbemycins (Ivomec, cydectin): Bind to proteins in throat (pharynx) of parasite leading to paralysis – parasite can’t eat anymore & dies of starvation! • Imidazothiazoles/Tetrahydropyrimidine (Levamisole, Pyrantel, Morantel): bind to acetylcholine receptors causing muscle paralysis. 1 9/8/2016 Status of Anthelmintics Efficacy Drug Host First 1st Report of Approved Resistance Benzimidazoles : Thiabendazole, Albendazole Sheep, 1961 1964 goat, Horse, 1962 1965 Imidothiazoles-tetrahydropyrimidines : Levamisole, Sheep 1970 1979 Pyrantel
  • Comparative Efficacies of Commercially Available Benzimidazoles Against Pseudodactylogyrus Infestations in Eels

    Comparative Efficacies of Commercially Available Benzimidazoles Against Pseudodactylogyrus Infestations in Eels

    DISEASES OF AQUATIC ORGANISMS Published October 4 Dis. aquat. Org. l Comparative efficacies of commercially available benzimidazoles against Pseudodactylogyrus infestations in eels ' Department of Fish Diseases, Royal Veterinary and Agricultural University, 13 Biilowsvej, DK-1870 Frederiksberg C, Denmark Department of Pharmacy, Royal Veterinary and Agricultural University, 13 Biilowsvej. DK-1870 Frederiksberg C,Denmark ABSTRACT: The antiparasitic efficacies of 9 benzimidazoles in commercially avalable formulations were tested (water bath treatments) on small pigmented eels Anguilla anguilla, expenmentally infected by 30 to 140 specimens of Pseudodactylogyrus spp. (Monogenea).Exposure time was 24 h and eels were examined 4 to 5 d post treatment. Mebendazole (Vermox; 1 mg 1-') eradicated all parasites, whereas luxabendazole (pure substance) and albendazole (Valbazen) were 100 % effective only at a concen- tration of 10 mg I-'. Flubendazole (Flubenol), fenbendazole (Panacur) and oxibendazole (Lodltac) (10 mg l-') caused a reduction of the infection level to a larger extent than did triclabendazole (Fasinex) and parbendazole (Helmatac).Thiabendazole (Equizole), even at a concentration as high as 100 mg l-', was without effect on Pseudodactylogyrus spp. INTRODUCTION range of commercially available benzimidazole com- pounds. If drug resistance will develop under practical The broad spectrum anthelmintic drug mebendazoIe eel-farm conditions in the future, it is likely to be was reported as an efficacious compound against infes- recognized during treatments with commercially avail- tations of the European eel Anguilla anguilla with gill able drug formulations. Therefore this type of drug parasitic monogeneans of the genus Pseudodactylo- preparations were used in the present study. gyms (Szekely & Molnar 1987, Buchmann & Bjerre- gaard 1989, 1990, Mellergaard 1989).
  • Bulletin Leading the Fight Against Heartworm Disease

    Bulletin Leading the Fight Against Heartworm Disease

    BULLETIN LEADING THE FIGHT AGAINST HEARTWORM DISEASE SEPTEMBER HEARTWORM 2017 Q&A VOLUME 44 No. 3 Heartworm History: In What Year Was Heartworm First INSIDE THIS ISSUE Treated? Page 4 From the President Page 8 Research Update Abstracts from the Literature Page 14 Heartworm Hotline: Role of Heat Treatment in Diagnostics Page 19 NEW! Best Practices: Minimizing Heartworm Transmission in Relocated Dogs uestions from members, prac- published in the 1998 AHS Symposium 1 titioners, technicians, and the Proceedings. Dr. Roncalli wrote, “The Page 21 Qgeneral public are often submit- first trial to assess the efficacy of a Welcome Our New AHS ted to the American Heartworm Society microfilaricide (natrium antimonyl tar- Student Liaisons (AHS) via our website. Two of our AHS trate) was conducted some 70 years Board members, Dr. John W.McCall and ago (1927) in Japan by S. Itagaki and R. Page 25 Dr. Tom Nelson, provided the resources Makino.2 Fuadin (stibophen), a trivalent In the News: Surgeons to answer this question: In What Year antimony compound, was tested, intra- Remove a Heartworm from Was Heartworm First Treated? venously, as a microfilaricide by Popescu the Femoral Artery of a Cat The first efforts to treat canine heart- in 1933 in Romania and by W.H. Wright worm disease date back to the 1920s. Dr. and P.C. Underwood in 1934 in the USA. Page 26 Nelson referenced a review article by Dr. In 1949, I.C. Mark evaluated its use Quarterly Update Raffaele Roncalli, “Tracing the History of intraperitoneally.” What’s New From AHS? Heartworms: A 400 Year Perspective,” Continues on page 7 American Heartworm Society / PO Box 8266, Wilmington, DE 19803-8266 Become an American Heartworm Society www.heartwormsociety.org / [email protected] fan on Facebook! Follow us on Twitter! OUR GENEROUS SPONSORS PLATINUM LEVEL PO Box 8266 Wilmington, DE 19803-8266 [email protected] www.heartwormsociety.org Mission Statement The mission of the American Heartworm Society is to lead the vet- erinary profession and the public in the understanding of heartworm disease.
  • United States Patent (19) 11 Patent Number: 5,861,142 Schick (45) Date of Patent: *Jan

    United States Patent (19) 11 Patent Number: 5,861,142 Schick (45) Date of Patent: *Jan

    USOO586 1142A United States Patent (19) 11 Patent Number: 5,861,142 Schick (45) Date of Patent: *Jan. 19, 1999 54 METHOD FOR PROMOTING HAIR, NAIL, 0 090 368 10/1983 European Pat. Off.. AND SKIN KERATINIZATION 0 187 012 7/1986 European Pat. Off.. 0 224 249 6/1987 European Pat. Off.. 76 Inventor: Mary Pichler Schick, 2027 Old Forge b 5. g i. As E. Way, Marietta, Ga. 30068 0 0 W.e "9CO * Notice: This patent issued on a continued pros- 95/16447 6/1995 WIPO. ecution application filed under 37 CFR OTHER PUBLICATIONS 1.53(d), and is subject to the twenty year patent term provisions of 35 U.S.C. Biochemistry Pharm., The interaction of benzimidazole Cat 154(a)(2). bamates with mammalian microtobule protein Vol. 28, p. 268O-2682. Davidse and Flach, “Differential Binding of Methyl 21 Appl. No.: 621,473 Benzimidazol-2-yl Carbamate to Fungal iustin S y 22 Filed: Mar. 25, 1996 Mechanism of Resistance to this Antimitotic Agent in 6 Mutant Strains of Aspergillus Nidulans”, Journal of Cell 51 Int. Cl. ....................................................... A61K 7/06 Biology, vol. 72, 1977, pp. 174-193. 52 U.S. Cl. ............................ 424/61; 424/701; 424/451; Fisher, et. al., “Efficacy of fenbenzalole and piperazine 424/464; 424/484; 424/489; 514/365; 514/395; against developing Stages of toxocara and toxascaris in 514/937; 514/944 dogs”, The Veterinary Record, vol. 132, No. 19, May 8, 58 Field of Search ..................................... 424/401, 701, 1943, pp. 473–475. 424/451, 464, 484, 489; 514/365, 395, 937, 944 (List continued on next page.) Primary Examiner Jvothsna Venkat 56) References Cited AOC, Agent, Or E".
  • Baylisascariasis

    Baylisascariasis

    Baylisascariasis Importance Baylisascaris procyonis, an intestinal nematode of raccoons, can cause severe neurological and ocular signs when its larvae migrate in humans, other mammals and birds. Although clinical cases seem to be rare in people, most reported cases have been Last Updated: December 2013 serious and difficult to treat. Severe disease has also been reported in other mammals and birds. Other species of Baylisascaris, particularly B. melis of European badgers and B. columnaris of skunks, can also cause neural and ocular larva migrans in animals, and are potential human pathogens. Etiology Baylisascariasis is caused by intestinal nematodes (family Ascarididae) in the genus Baylisascaris. The three most pathogenic species are Baylisascaris procyonis, B. melis and B. columnaris. The larvae of these three species can cause extensive damage in intermediate/paratenic hosts: they migrate extensively, continue to grow considerably within these hosts, and sometimes invade the CNS or the eye. Their larvae are very similar in appearance, which can make it very difficult to identify the causative agent in some clinical cases. Other species of Baylisascaris including B. transfuga, B. devos, B. schroeder and B. tasmaniensis may also cause larva migrans. In general, the latter organisms are smaller and tend to invade the muscles, intestines and mesentery; however, B. transfuga has been shown to cause ocular and neural larva migrans in some animals. Species Affected Raccoons (Procyon lotor) are usually the definitive hosts for B. procyonis. Other species known to serve as definitive hosts include dogs (which can be both definitive and intermediate hosts) and kinkajous. Coatimundis and ringtails, which are closely related to kinkajous, might also be able to harbor B.
  • COMBINED LIST of Particularly Hazardous Substances

    COMBINED LIST of Particularly Hazardous Substances

    COMBINED LIST of Particularly Hazardous Substances revised 2/4/2021 IARC list 1 are Carcinogenic to humans list compiled by Hector Acuna, UCSB IARC list Group 2A Probably carcinogenic to humans IARC list Group 2B Possibly carcinogenic to humans If any of the chemicals listed below are used in your research then complete a Standard Operating Procedure (SOP) for the product as described in the Chemical Hygiene Plan. Prop 65 known to cause cancer or reproductive toxicity Material(s) not on the list does not preclude one from completing an SOP. Other extremely toxic chemicals KNOWN Carcinogens from National Toxicology Program (NTP) or other high hazards will require the development of an SOP. Red= added in 2020 or status change Reasonably Anticipated NTP EPA Haz list COMBINED LIST of Particularly Hazardous Substances CAS Source from where the material is listed. 6,9-Methano-2,4,3-benzodioxathiepin, 6,7,8,9,10,10- hexachloro-1,5,5a,6,9,9a-hexahydro-, 3-oxide Acutely Toxic Methanimidamide, N,N-dimethyl-N'-[2-methyl-4-[[(methylamino)carbonyl]oxy]phenyl]- Acutely Toxic 1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU) Prop 65 KNOWN Carcinogens NTP 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) IARC list Group 2A Reasonably Anticipated NTP 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (Lomustine) Prop 65 1-(o-Chlorophenyl)thiourea Acutely Toxic 1,1,1,2-Tetrachloroethane IARC list Group 2B 1,1,2,2-Tetrachloroethane Prop 65 IARC list Group 2B 1,1-Dichloro-2,2-bis(p -chloropheny)ethylene (DDE) Prop 65 1,1-Dichloroethane
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • Computational Studies of Drug Repurposing Targeting P-Glycoprotein Mediated Multidrug-Resistance Phenotypes in Agents of Neglect

    Computational Studies of Drug Repurposing Targeting P-Glycoprotein Mediated Multidrug-Resistance Phenotypes in Agents of Neglect

    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.12.147926; this version posted June 12, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Computational studies of drug repurposing targeting P- glycoprotein mediated multidrug-resistance phenotypes in agents of neglected tropical diseases Nivedita Jaishankar 1, Sangeetha Muthamilselvan 2, Ashok Palaniappan 1,2* 1 Department of Biotechnology, Sri Venkateswara College of Engineering, Post Bag No. 1, Pennalur, Sriperumbudur Tk 602117. India 2 Department of Bioinformatics, School of Chemical and BioTechnology, SASTRA Deemed University, Thanjavur 613401. India * Corresponding author: [email protected] ABSTRACT Mammalian ABCB1 P-glycoprotein is an ATP- dependent efflux pump with broad substrate specificity associated with cellular drug resistance. Homologous to this role in mammalian biology, the P-glycoprotein of agents of neglected tropical diseases (NTDs) mediates the emergence of multidrug- resistance phenotypes. The clinical and socioeconomic implications of NTDs are exacerbated by the lack of research interest among Big Pharma for treating such conditions. This work aims to characterise P-gp homologues in certain agents of key NTDs, namely (1) Protozoa: Leishmania major, Trypanosoma cruzi; (2) Helminths: Onchocerca volvulus, Schistosoma mansoni. PSI-BLAST searches against the genome of each of these organisms confirmed the presence of P-gp homologues. Each homologue was aligned against five P- gp sequences of known structure, to identify the most suitable template based on sequence homology, phylogenetic nearest neighbor, and query coverage.
  • Equimax & Eraquell Oral Gel for Horses

    Equimax & Eraquell Oral Gel for Horses

    Equimax & Eraquell Oral Gel for Horses Annual Wormer Pack [active ingredients: Ivermectin & Praziquantel] (POM-VPS) Revised AN Equimax Oral Gel for Horses January 2013 01009/2012 Eraquell Oral Gel for Horses December 2015 01163/2015 Page 1 of 15 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Equimax Oral Gel for Horses 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each gram of Equimax contains Active substances Ivermectin ........................................................ 18.7 mg Praziquantel ..................................................... 140.3 mg Excipients Titanium dioxide (E171) ................................... 20 mg Propylene glycol ............................................... 731 mg For a full list of excipents, see section 6.1 3. PHARMACEUTICAL FORM Oral gel. 4. CLINICAL PARTICULARS 4.1 Target species Horses. 4.2 Indications for use, specifying the target species For the treatment of mixed cestode and nematode or arthropod infestations, due to adult and immature roundworms, lungworms, bots and tapeworms in horses: Nematodes Large-strongyle: Strongylus vulgaris (adult and arterial larvae) Strongylus edentatus (adult and L4 tissue larval stages) Strongylus equinus (adult) Triodontophorus spp. (adult) Small-strongyle: Cyathostomum: Cylicocyclus spp., Cylicostephanus spp., Cylicodontophorus spp., Gyalocephalus spp. (adult and non-inhibited mucosal larvae). Parascaris: Parascaris equorum (adult and larvae). Page 2 of 15 Oxyuris: Oxyuris equi (larvae). Trichostrongylus:Trichostrongylus
  • Chemotherapy of Gastrointestinal Helminths

    Chemotherapy of Gastrointestinal Helminths

    Chemotherapy of Gastrointestinal Helminths Contributors J. H. Arundel • J. H. Boersema • C. F. A. Bruyning • J. H. Cross A. Davis • A. De Muynck • P. G. Janssens • W. S. Kammerer IF. Michel • M.H. Mirck • M.D. Rickard F. Rochette M. M. H. Sewell • H. Vanden Bossche Editors H. Vanden Bossche • D.Thienpont • P.G. Janssens UNIVERSITATS- BlfiUOTHElC Springer-Verlag Berlin Heidelberg New York Tokyo Contents CHAPTER 1 Introduction. A. DAVIS A. Pathogenic Mechanisms in Man 1 B. Modes of Transmission 2 C. Clinical Sequelae of Infection 3 D. Epidemiological Considerations 3 E. Chemotherapy 4 F. Conclusion 5 References 5 CHAPTER 2 Epidemiology of Gastrointestinal Helminths in Human Populations C. F. A. BRUYNING A. Introduction 7 B. Epidemiological or "Mathematical" Models and Control 8 C. Nematodes 11 I. Angiostrongylus costaricensis 11 II. Anisakis marina 12 III. Ascaris lumbricoides 14 IV. Capillaria philippinensis 21 V. Enterobius vermicularis 23 VI. Gnathostoma spinigerum 25 VII. Hookworms: Ancylostoma duodenale and Necator americanus . 26 VIII. Oesophagostoma spp 32 IX. Strongyloides stercoralis 33 X. Ternidens deminutus 34 XI. Trichinella spiralis 35 XII. Trichostrongylus spp 38 XIII. Trichuris trichiura 39 D. Trematodes 41 I. Echinostoma spp 41 II. Fasciolopsis buski 42 III. Gastrodiscoides hominis 44 IV. Heterophyes heterophyes 44 V. Metagonimus yokogawai 46 X Contents E. Cestodes 47 I. Diphyllobothrium latum 47 II. Dipylidium caninum 50 III. Hymenolepis diminuta 51 IV. Hymenolepis nana 52 V. Taenia saginata 54 VI. Taenia solium 57 VII. Cysticercosis cellulosae 58 References 60 CHAPTER 3 Epidemiology and Control of Gastrointestinal Helminths in Domestic Animals J. F. MICHEL. With 20 Figures A. Introduction 67 I.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE